Retinal Vein Occlusion Treatment Market

Retinal Vein Occlusion Treatment Market Snapshot (2023 to 2033)

The global retinal vein occlusion treatment market is expected to be valued at USD 2.3 billion in 2023 and is projected to exhibit a compound annual growth rate (CAGR) of 5.9% to reach USD 4.7 billion during forecast 2023 to 2033. Retinal vein occlusion is one of the most prevalent retinal vascular illnesses in older individuals, primarily affecting people over the age of 65. Age is a major potential risk for retinal vein occlusion. As the geriatric population rises, it is expected that the incidence of retinal vein occlusion will emerge as well.

Players in the retinal vein occlusion treatment market are expanding their capacity for producing corticosteroid drugs, which can aid in combating the inflammatory elements that cause edema. Medical practitioners, on the other side, are increasingly becoming proficient in focal laser therapy. This treatment applies lasers to places of swelling, allowing edema to reduce. Many retinal vein occlusion market stakeholders are investing more in pan-retinal photocoagulation therapy advancement and research. In instances of BRVO with neovascularization or macular edema, anti-vascular endothelial growth factor (anti-VEGF) medicines including Lucentis, Avastin, and Eylea are often used.

Moreover, increased medication authorization for the diagnosis of RVO patients contributes to industry growth. For instance, the Food and Drug Administration (FDA) certified the first biosimilar drug, Byooviz (ranibizumab-nuna) evolved by Samsung Bioepis, for the treatment of individuals with macular degeneration and other eye diseases such as RVO in September 2021. This authorization should augment overall growth.

Moreover, increased medication authorization for the diagnosis of RVO patients contributes to industry expansion. For instance, the Food and Drug Administration (FDA) certified the first biosimilar drug, Byooviz (ranibizumab-nuna) evolved by Samsung Bioepis, for the treatment of individuals with macular degeneration and other eye diseases such as RVO in September 2021. This authorization should augment overall growth.

Due to various effective healthcare facilities, an increment in the pervasiveness of eye disorders, sophisticated technology, and a boost in the ageing population, North America held a significant portion of the global retinal vein occlusion market in 2022. From 2023 to 2033, the Asia Pacific retinal vein occlusion market is predicted to grow at a 6.5% CAGR. The increasing prevalence of eye conditions in Asia Pacific, particularly in China, Singapore, Indonesia, and other Southeast Asian countries, as well as rising healthcare spending, are predicted to propel market expansion in Asia Pacific from 2023 to 2033.

The retinal vein occlusion industry in the Middle East and Africa is expected to grow due to the presence of a sophisticated medical system. Due to limited access to medical infrastructure and the sluggish advancement of the healthcare industry, the MEA market is expected to grow gradually. Nations such as Kuwait and Qatar, on the other hand, are focusing more on the medical industry and burgeoning healthcare facilities, which will strengthen the region's industry. Considering the aforementioned facts and figures, the market is projected to exhibit a good rate of growth.

Data Points	Key Statistics
Expected Market Value (2023)	USD 2.3 billion
Anticipated Forecast Value (2033)	USD 4.7 billion
Projected Growth Rate (2023 to 2033)	5.9% CAGR

2018 to 2022 Retinal Vein Occlusion Treatment Demand Analysis vs. Forecast 2023 to 2033

The decline in industry growth was mainly due to the COVID-19 pandemic, which has resulted in strict containment approaches such as social distancing, remote employment, and the closure of industries and other economic operations, deriving in organizational hardships. The entire distribution chain has been impacted, which has had a negative impact on the retinal vein occlusion treatment market in the past.

However, now, that the industries are getting back to their normal functioning, the global demand for retinal vein occlusion treatment is projected to increase at a CAGR of 5.9% during the forecast period between 2023 and 2033, reaching a total of USD 4.7 billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 5%.

Which are Some Prominent Drivers of the Retinal Vein Occlusion Treatment Market?

The rising prevalence of Atherosclerosis and diabetes drives market expansion

The increased incidence of atherosclerosis and diabetes is predicted to drive market expansion. Because atherosclerosis is primarily asymptomatic, determining the prevalence rate is hard. Atherosclerosis is widely regarded as the leading cause of cardiovascular disease. As a result, the increasing incidence of cardiovascular diseases is attributed to the retinal vein occlusion treatment industry growth.

Based on the International Diabetes Federation (IDF), approximately 537 million adults suffered from diabetes in 2021, with this figure expected to rise to 643 million by 2030 and 783 million by 2045. In addition, approximately 610,000 deaths occur from heart disease in the United States annually. That equates to one out of every four deaths.

Coronary heart disease is the main cause of mortality in the Western world, claiming the lives of over 370,000 people each year as per the report published in the National Library of Medicine. As a result, expanding the pervasiveness of secondary conditions may boost RVO incidence and industry growth.

Availability of Multiple Medical Therapies to fuel Market Growth

Presently, there is no therapeutic option to reverse retinal vein occlusions. There are, nevertheless, numerous medical therapies obtainable to control RVO complications. Anti-VEGF injections, corticosteroid drugs, focal laser therapy, and pan-retinal photocoagulation therapy are a few of the therapy methods. Anti-VEGF injection therapy is regarded as the first curative therapy for patient populations with BRVO or CRVO who have macular edema.

Anti-VEGF therapy has resulted in significant advances in macular edema patients. For those who suffer from macular edema, corticosteroids, such as dexamethasone implant (OZURDEX) are termed second-line therapy. Therefore, the prevalence of various therapies is predicted to drive market growth.

What are the Challenges Projected to be Faced by the Market?

High Costs to Hinder Market Growth

The demand is anticipated to be hindered by the present unmet medical needs in the retinal vein occlusion industry for care that restores vision while remaining inexpensive.

There is no doubt that the emergence of biosimilars into the Retinal vein occlusion market will reduce expansion in the forthcoming years. During the projected timeframe, high treatment-related expenses and linked side effects of these treatments are anticipated to stymie demand.

Region-Wise Insights

What Makes North America the Largest Market for Retinal Vein Occlusion Treatment?

Extensive Development of Ophthalmology Infrastructure of the Pharmaceutical Industry to drive growth

North America would retain a huge proportion throughout the forecast timeframe. The USFDA's authorization of advanced anti-VEGF medicines in the USA, the pharma industry's massive ophthalmology infrastructure, and recurring medical studies for retinal ailments all contribute to the industry's growth.

Moreover, according to the report published in Vitreous Retina Macula Consultants of New York, New York ophthalmologists and retinal ocular specialists release more research on the therapeutic interventions for branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) in the leading peer-reviewed publications than any other personal or scholarly group in the USA. Also, they created numerous existing theories in retinal disease and several of the best therapeutic approaches recognized worldwide. As a result, this factor is expected to propel the market.

Why is Europe Considered a Lucrative Region for the Retinal Vein Occlusion Treatment Market?

Regulatory Drug Approvals drive Regional Market Growth

Europe is expected to have the second-largest sales volume during the forecast years owing to the high prevalence of regulatory drug approvals. The Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom approved marketing approval for Ximluci, a ranibizumab biosimilar created in collaboration between STADA Arzneimittel and Xbrane Biopharma, in January 2023. Since the approval of Teva Pharmaceuticals' Ongavia in May 2022, this is the 2nd ranibizumab biosimilar for the UK industry. Ranibizumab is a vascular endothelial growth variable obstacle used to cure retinal diseases such as retinal vein occlusion.

According to a 2018 Pubmed report, the random-effects gathered incidence of RVO in Europeans over the age of 55 was 0.7%. The overall population of affected people in the EU is expected to increase by nearly 20%, from 900,000 in 2018 to 1.1 million in 2050. The rise of a huge aged population, along with high healthcare investment, are the other attributes driving the retinal vein occlusion market expansion in this region.

Category-Wise Insights

Which Type Leads the Market for Retinal Vein Occlusion Treatment?

Branch Retinal Vein Occlusion segment held the highest market share globally

In 2022, the branch retinal vein occlusion segment held the largest global retinal vein occlusion therapeutics revenue growth. As a result of the growing incidence of elevated blood pressure, cardiovascular disease, and glaucoma, this segment is predicted to dominate the market. This segment is anticipated to expand at a CAGR of 6% over the forecast timeframe.

By End User, Which Segment is Projected to Lead the Market?

Hospitals are Estimated to Hold the Largest Share

In 2022, the hospital segment led the market, accounting for 46% of total revenue. Hospitals are usually regarded as primary healthcare systems, and the patient population's priority for hospitals for the assessment and treatment of chronic disorders is also stirring up segment growth.

Market Competition

Key players in the Retinal Vein Occlusion Treatment market are AbbVie, Roche, Regeneron Pharmaceuticals, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Kodiak Sciences Inc, Chugai Pharmaceuticals, Novartis AG. Some of the latest developments by the manufacturers are below

• Novartis AG stated highly supportive of the initial interpretable Phase III outcomes of a clinical study examining the efficacy and security of Beovu in December 2020. Beovu by Novartis put Regeneron's anti-VEGF Eylea, one of the renowned treatments for diabetic macular edema, in direct competition.
• Roche is presently conducting Phase III trials to determine the effectiveness and security of Faricimab in patient populations with macular edema secondary to BRVO and CRVO, with the drug anticipated to be approved by 2023 according to the findings.

Report Scope

Report Attribute	Details
Market Value in 2023	USD 2.3 billion
Market Value in 2033	USD 4.7 billion
Growth Rate	CAGR of 5.9% from 2023 to 2033
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in USD Billion and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered	Drug Class, Type, Diagnosis, End User, Region
Regions Covered	North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa
Key Countries Profiled	United States, Canada, Brazil, Mexico, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel
Key Companies Profiled	AbbVie; F. Hoffmann- La Roche AG; Regeneron Pharmaceuticals Inc.; Taiwan Liposome Company; Aerie Pharmaceuticals Inc.; Graybug Vision; Outlook Therapeutics; Kodiak Sciences Inc.; Chugai Pharmaceutical Co. Ltd.; Novartis AG

Key Segments Profiled in the Retinal Vein Occlusion Treatment Industry Survey

By Drug Class:

• Ranibizumab
• Dexamethasone
• Aflibercept
• Bevacizumab

By Type:

• Central Retinal Vein Occlusion
• Branch Retinal Vein Occlusion

By Diagnosis:

• Optical Coherence Tomography
• Fundoscopic Examination
• Fluorescein Angiography

By End User:

• Hospitals
• Research and Academics
• Specialty Clinics

By Region:

• North America
• Europe
• East Asia
• South Asia
• Oceania
• Latin America
• Middle East and Africa (MEA)

Frequently Asked Questions

What is the Market Value in 2023?

The market value for 2023 is USD 2.3 billion.

What is the Market Growth Outlook?

Through 2033, market sales are likely to rise at a 5.9% CAGR.

What was the Historical CAGR for the Market?

The market rose at a 5% CAGR from 2018 to 2022.

What could Limit the Retinal Vein Occlusion Treatment Sales?

Growing preference for biosimilars could hinder market growth.

Which type of Segment Leads the Market?

Branch retinal vein occlusion is likely to be the key type segment through 2033.